The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study

The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study

Abstract Background According to the EASL and AASLD guidelines, the recommended treatment for patients who failed to achieve a sustained virologic response (SVR) on prior interferon-based triple therapy with protease inhibitors (PI), is a combination of sofosbuvir and NS5A inhibitors. Polish nationa...

Full description

Bibliographic Details
Main Authors: Ewa Janczewska, Dorota Zarębska-Michaluk, Hanna Berak, Anna Piekarska, Andrzej Gietka, Dorota Dybowska, Włodzimierz Mazur, Teresa Belica-Wdowik, Witold Dobracki, Magdalena Tudrujek-Zdunek, Zbigniew Deroń, Iwona Buczyńska, Marek Sitko, Agnieszka Czauż-Andrzejuk, Beata Lorenc, Jolanta Białkowska-Warzecha, Jolanta Citko, Łukasz Laurans, Jerzy Jaroszewicz, Łukasz Socha, Olga Tronina, Brygida Adamek, Andrzej Horban, Waldemar Halota, Barbara Baka-Ćwierz, Krzysztof Tomasiewicz, Krzysztof Simon, Aleksander Garlicki, Marta Wawrzynowicz-Syczewska, Robert Flisiak
Format: Article
Language:English
Published: BMC 2018-11-01
Series:BMC Infectious Diseases
Subjects:
Chronic hepatitis C
Liver cirrhosis
Protease inhibitors
Retreatment
Sustained virologic response
Online Access:http://link.springer.com/article/10.1186/s12879-018-3465-2

Similar Items

Similar Items